Contact
Please use this form to send email to PR contact of this press release:
Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD
TO:
Please use this form to send email to PR contact of this press release:
Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD
TO: